STOCK TITAN

Relief Therapeut - RLFTY STOCK NEWS

Welcome to our dedicated page for Relief Therapeut news (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on Relief Therapeut stock.

Overview of Relief Therapeutics (RLFTY)

Relief Therapeutics is a commercial‐stage biopharmaceutical company committed to advancing innovative treatment options in select specialty, unmet, and rare diseases. Operating with a focus on conditions such as rare metabolic disorders and dermatological conditions, the company is dedicated to improving therapeutic outcomes through state-of-the-art drug formulation and a robust clinical development pipeline. With proprietary technologies including the TEHCLO™ and Physiomimic™ platforms, Relief Therapeutics develops patient-friendly formulations that enhance treatment adherence, ensuring effective management for complex, chronic conditions.

Core Business Areas and Technological Innovations

The company focuses on three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. Its pipeline includes innovatively formulated treatments such as a highly concentrated liquid formulation for phenylketonuria (PKU) designed to reduce the medication volume, thereby improving patient compliance. Additionally, Relief Therapeutics is advancing solutions for conditions like epidermolysis bullosa (EB) by employing a stabilized hypochlorous acid solution, which not only promotes wound healing but also effectively manages infections by targeting pathogenic bacteria while preserving beneficial microbiome diversity.

Clinical Development and Research Rigor

Relief Therapeutics maintains a rigorous clinical development strategy characterized by multiple proof-of-concept and pilot trials. The results from these studies have shown promising bioequivalence and patient compliance parameters, enabling more flexible dosing options compared to standard treatments. Each clinical investigation is crafted to address specific treatment challenges, thereby ensuring that the solutions are both innovative and closely aligned with patient needs.

Market Position and Strategic Collaborations

Headquartered in Geneva, the company operates on a global scale, with its shares listed on the SIX Swiss Exchange and quoted on the U.S. OTCQB market. Relief Therapeutics employs a balanced business model that combines marketed, revenue-generating products with a forward-looking clinical development pipeline. Strategic licensing and distribution partnerships further enhance its market presence, allowing the company to leverage both its novel technologies and existing products to meet uncompromised quality and compliance standards required by healthcare providers worldwide.

Competitive Differentiators and Patient-Centric Approach

What sets Relief Therapeutics apart is its commitment to creating formulations that are not only efficacious but also tailored for patient convenience. By reducing the dosage volume and offering flexible administration options, its treatments help mitigate common adherence challenges in rare diseases, particularly those affecting pediatric and multi-age patient populations. The company’s investment in innovative technology, coupled with strategically designed clinical trials, positions it uniquely in a competitive landscape where scientific rigor and patient outcomes are at the forefront.

Industry Terminology and Regulatory Milestones

  • Bioequivalence: Clinical studies comparing the novel formulations with established treatments to ensure similar therapeutic exposures.
  • Proprietary Formulation Technology: Use of patented platforms like TEHCLO™ that underpin the company’s innovative drug delivery mechanisms.
  • Regulatory Submissions: Meticulous planning to achieve pivotal trial results and support potential applications under frameworks such as the 505(b)(2) NDA pathway in the United States.

Overall, Relief Therapeutics demonstrates an unwavering focus on enhancing the quality of life for patients with challenging and rare conditions through a well-orchestrated blend of innovative technology, clinical expertise, and comprehensive regulatory strategy. This detailed approach serves both to inform and to guide financial analysts and healthcare professionals seeking an in-depth understanding of the company’s operations and business model.

Rhea-AI Summary

Relief Therapeutics has received a Notice of Allowance from the European Patent Office for its patent application covering RLF-TD011, a treatment for wounds caused by epidermolysis bullosa (EB). The patent, set to protect RLF-TD011 in key European countries until 2040, covers Relief's proprietary hypochlorous acid solutions. Corresponding applications are under review in other major markets, including the U.S. and China.

RLF-TD011 has previously received orphan drug designation from the U.S. FDA for EB, potentially providing incentives such as market exclusivity upon approval. Giorgio Reiner, Relief's chief scientific officer, stated that this patent grant validates their efforts to develop novel treatments for rare diseases and strengthens the protection of their innovation as they advance RLF-TD011's development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics has announced promising preliminary results from its proof-of-concept clinical trial evaluating RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic condition. The study focused on the effects of RLF-TD011 on microbiome diversity in EB wounds.

Key findings include:

  • Statistically significant reduction in Staphylococcus aureus
  • Increase in beneficial bacteria in EB wounds
  • Marked improvement in alpha microbiome diversity
  • Notable correlation between wound healing and Staphylococcus aureus reduction

Prof. Amy Paller, Principal Investigator and Chair of Dermatology at Northwestern University, highlighted the importance of addressing Staphylococcus aureus overgrowth in EB patients. The preliminary results suggest RLF-TD011's potential to target a critical need in EB treatment, potentially improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.56%
Tags
-
Rhea-AI Summary

Relief Therapeutics reported positive topline results from its proof-of-concept clinical study evaluating RLF-OD032, a concentrated liquid formulation of sapropterin dihydrochloride, for treating phenylketonuria (PKU). The four-way crossover pilot study compared RLF-OD032's pharmacokinetics with KUVAN® powder for oral solution. Topline data showed that RLF-OD032 administered under fed conditions, with or without water, achieved similar peak and total exposure of sapropterin dihydrochloride as KUVAN® under fed conditions with water, meeting FDA bioequivalence study requirements.

Relief plans to advance RLF-OD032 into a pivotal bioequivalence trial as part of the 505(b)(2) NDA submission process in the United States, following FDA pre-IND meeting guidance. The company believes RLF-OD032's potential for administration without water and low-volume dosage offers a unique, portable solution for PKU patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
Rhea-AI Summary

Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) has completed the clinical phase of its proof-of-concept study for RLF-OD032, a treatment for phenylketonuria (PKU). The study aims to compare RLF-OD032 with an existing sapropterin dihydrochloride product, focusing on bioavailability under different conditions. Topline results are expected in October 2024, which will guide further development towards a pivotal trial and potential regulatory submission in the US.

RLF-OD032 is a highly concentrated liquid formulation of sapropterin dihydrochloride, designed to lower blood phenylalanine in PKU patients. It offers a more patient-friendly solution by reducing the required medication volume, potentially improving compliance, especially among pediatric patients. If approved, RLF-OD032 would be the first portable, ready-to-use liquid formulation of sapropterin dihydrochloride.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Relief Therapeutics announced that interim data from their clinical trial evaluating PKU GOLIKE® will be presented at the SSIEM 2024 Annual Symposium in Porto, Portugal. This study, carried out by the Inherited Metabolic Disorders Unit at Birmingham Children's Hospital, UK, focuses on controlling overnight phenylalanine (Phe) fluctuations in pediatric patients with phenylketonuria (PKU).

The study compares the benefits of PKU GOLIKE to standard amino acid protein substitutes. Preliminary results indicate that PKU GOLIKE reduces blood phenylalanine levels and increases blood tyrosine levels overnight, which could prevent toxic Phe accumulation during prolonged fasting periods. Final results will be reported after ongoing data analysis.

For more information, visit clinicaltrials.gov (NCT05487378).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) reported strong financial results for H1 2024, with revenue up 85% and operating expenses down 45%. The company's cash reserves of CHF 15.1 million are expected to fund operations into at least 2026. Key developments include:

1. Anticipated results from the RLF-TD011 trial for epidermolysis bullosa wound treatment
2. Progress in the RLF-OD032 pilot PK study for phenylketonuria, with potential NDA filing by mid- to late 2025
3. Streamlined operations and cost-reduction initiatives
4. Stable R&D investments despite overall expense reduction

The company remains debt-free and expects continued revenue growth to support its development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Relief Therapeutics has secured up to $11 million in non-dilutive funding through the sale of royalty interests to SWK Funding The deal includes $5.75 million upfront and $5.25 million in potential milestone payments. The funds will support the development of RLF-TD011, a topical spray for epidermolysis bullosa, and other pipeline advancements.

The agreement covers royalties from OLPRUVA, GOLIKE, and CAMBIA. Relief retains significant upside potential, with SWK returning 80% of OLPRUVA royalties over $2.25 million annually and all royalties over $4.5 million. For GOLIKE, SWK will return 80% of royalties over $1.32 million annually and all over $1.98 million. The deal terminates when SWK receives 2.75 times its invested capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Relief Therapeutics announced the results of its Annual General Meeting (AGM) on June 27, 2024, in Geneva. Key outcomes include approval of the 2023 annual report and financial statements, and the decision to carry forward the 2023 financial year loss. While the board of directors and executive committee were not granted discharge for the financial year 2023, all other resolutions were approved by a large majority. This includes the re-election of Dr. Raghuram Selvaraju as chairman, and the re-election of key board members and auditors. The company's efforts to address shareholder concerns continue, especially regarding the board's discharge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Relief Therapeutics has announced several executive changes. Interim CEO Michelle Lock's contract expired on May 31, 2024, and she will not seek re-election to the Board of Directors. CFO Andrew Einhorn and CHRO Melinda Keegan have also departed. The Board of Directors will oversee the company's operations while evaluating options to optimize the senior management team. Jeremy Meinen will remain in a senior role. The Board is focused on maximizing the value of Relief Therapeutics' therapeutic product portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Relief Therapeutics has announced its Annual General Meeting (AGM) of shareholders, scheduled for June 27, 2024, at 11:00 a.m. CEST in Geneva, Switzerland. The agenda includes key items such as the adoption of the 2023 annual report and financial accounts, appropriation of the annual result, discharge of the board of directors and executive committee, approval of compensation for board members, re-election of existing board members and its chairman, and election of the nomination and compensation committee. Shareholders will also vote on the 2023 compensation report and re-elect the independent voting rights representative and auditors. The formal notice, including attendance details and registration requirements, will be sent to registered shareholders on June 5, 2024. The full agenda is available on the Relief website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Relief Therapeut (RLFTY)?

The current stock price of Relief Therapeut (RLFTY) is $3 as of April 1, 2025.

What is the market cap of Relief Therapeut (RLFTY)?

The market cap of Relief Therapeut (RLFTY) is approximately 40.1M.

What is Relief Therapeutics' primary business focus?

Relief Therapeutics is dedicated to developing innovative treatment options for select specialty, unmet, and rare diseases. Its focus is on creating patient-friendly formulations that improve adherence and efficacy in challenging clinical areas.

How does Relief Therapeutics generate revenue?

The company generates revenue through a balanced mix of marketed, revenue-generating products and a targeted clinical development pipeline. It also leverages licensing and distribution partnerships to commercialize legacy and innovative products.

What proprietary technologies does the company use?

Relief Therapeutics employs proprietary platforms such as TEHCLO™ and Physiomimic™, which underpin its innovative drug formulation processes. These technologies help in developing formulations that enhance drug bioavailability and patient compliance.

Which therapeutic areas are targeted by Relief Therapeutics?

The company focuses on three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. Its development programs are tailored to address the specific challenges presented by these conditions.

How does the RLF-OD032 formulation improve treatment for PKU patients?

RLF-OD032 is designed as a highly concentrated liquid formulation that significantly reduces the required medication volume compared to existing treatments. This approach enhances patient convenience and adherence, making it a more user-friendly option for PKU management.

What benefits does RLF-TD011 offer for epidermolysis bullosa patients?

RLF-TD011 is a stabilized hypochlorous acid solution that shows promising antimicrobial properties, promoting wound healing by reducing pathogenic bacteria such as Staphylococcus aureus. Clinical trials have shown improvements in wound closure and overall microbiome diversity in EB patients.

What strategic partnerships does Relief Therapeutics engage in?

The company collaborates with various licensing and distribution partners to commercialize its products globally. These strategic alliances help extend market reach and optimize resource allocation across its portfolio.

Where is Relief Therapeutics headquartered and how is it traded?

Relief Therapeutics is headquartered in Geneva, Switzerland. The company is listed on the SIX Swiss Exchange under the symbol RLF and is also quoted on the U.S. OTCQB market under the symbols RLFTF and RLFTY.
Relief Therapeut

OTC:RLFTY

RLFTY Rankings

RLFTY Stock Data

40.13M
9.56M
Biotechnology
Healthcare
Link
Switzerland
Geneva